Tearsheet

Ardent Health (ARDT)


Market Price (12/26/2025): $8.965 | Market Cap: $1.3 Bil
Sector: Health Care | Industry: Health Care Facilities

Ardent Health (ARDT)


Market Price (12/26/2025): $8.965
Market Cap: $1.3 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 16%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 12%, FCF Yield is 12%
Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 132%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%
Key risks
ARDT key risks include [1] significant adverse accounting adjustments to revenue and liability reserves, Show more.
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Oncology Treatments, Show more.
 
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 16%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 12%, FCF Yield is 12%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Oncology Treatments, Show more.
3 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 132%
4 Key risks
ARDT key risks include [1] significant adverse accounting adjustments to revenue and liability reserves, Show more.

Valuation, Metrics & Events

ARDT Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Here are five key points explaining the approximate -29.3% movement in Ardent Health (ARDT) stock from August 31, 2025, to December 26, 2025: 1. Lowered FY2025 Earnings Guidance: Ardent Health issued its Q3 earnings results on November 12, 2025, reporting earnings per share (EPS) of $0.52 against an expected $0.42, and revenue of $1.58 billion versus an expected $1.55 billion. However, the company's full-year 2025 EPS guidance of $0.85–$1.03 fell below the consensus forecast of approximately $1.23, which likely contributed to investor concern.

2. Analyst Downgrades and Trimmed Price Targets: Following financial announcements, several brokerage firms, including RBC, Guggenheim, JPMorgan, and KeyCorp, reportedly trimmed their price targets or ratings for ARDT stock. As of December 25, 2025, Ardent Health received a consensus recommendation of "Hold" from twelve analysts, with an average 12-month target price of $14.67, indicating a cautious outlook from the financial community.

Show more

Stock Movement Drivers

Fundamental Drivers

The -32.0% change in ARDT stock from 9/25/2025 to 12/25/2025 was primarily driven by a -21.2% change in the company's Net Income Margin (%).
925202512252025Change
Stock Price ($)13.198.97-31.99%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)6198.626325.552.05%
Net Income Margin (%)4.11%3.24%-21.15%
P/E Multiple7.266.18-14.97%
Shares Outstanding (Mil)140.37141.23-0.61%
Cumulative Contribution-32.00%

LTM = Last Twelve Months as of date shown

Market Drivers

9/25/2025 to 12/25/2025
ReturnCorrelation
ARDT-32.0% 
Market (SPY)4.9%31.0%
Sector (XLV)16.2%16.2%

Fundamental Drivers

The -32.6% change in ARDT stock from 6/26/2025 to 12/25/2025 was primarily driven by a -25.5% change in the company's P/E Multiple.
626202512252025Change
Stock Price ($)13.318.97-32.61%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)6024.266325.555.00%
Net Income Margin (%)3.73%3.24%-13.08%
P/E Multiple8.306.18-25.54%
Shares Outstanding (Mil)140.06141.23-0.83%
Cumulative Contribution-32.61%

LTM = Last Twelve Months as of date shown

Market Drivers

6/26/2025 to 12/25/2025
ReturnCorrelation
ARDT-32.6% 
Market (SPY)13.1%28.2%
Sector (XLV)16.6%15.5%

Fundamental Drivers

The -44.2% change in ARDT stock from 12/25/2024 to 12/25/2025 was primarily driven by a -82.1% change in the company's P/E Multiple.
1225202412252025Change
Stock Price ($)16.078.97-44.18%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)4951.746325.5527.74%
Net Income Margin (%)1.32%3.24%144.66%
P/E Multiple34.536.18-82.11%
Shares Outstanding (Mil)140.96141.23-0.19%
Cumulative Contribution-44.18%

LTM = Last Twelve Months as of date shown

Market Drivers

12/25/2024 to 12/25/2025
ReturnCorrelation
ARDT-44.2% 
Market (SPY)15.8%25.9%
Sector (XLV)13.3%30.8%

Fundamental Drivers

null
null

Market Drivers

12/26/2023 to 12/25/2025
ReturnCorrelation
ARDT  
Market (SPY)48.3%24.5%
Sector (XLV)18.5%28.1%

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
ARDT Return-48%-48%
Peers Return51%64%-30%13%12%25%172%
S&P 500 Return16%27%-19%24%23%18%115%

Monthly Win Rates [3]
ARDT Win Rate40%42% 
Peers Win Rate55%65%45%55%55%57% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
ARDT Max Drawdown-52% 
Peers Max Drawdown-53%-6%-53%-19%-11%-15% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: HCA, THC, UHS, CYH, SGRY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

ARDT has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique KeyEventXLVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-16.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven19.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven599 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-28.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven40.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven116 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-15.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven18.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven326 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-40.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven68.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,100 days1,480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Ardent Health (ARDT)

We are the fourth largest privately held, for-profit operator of hospitals and a leading provider of healthcare services in the United States(1). We currently operate in eight growing mid-sized urban markets across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. We deliver care through a system of 30 acute care hospitals, more than 200 sites of care, and over 1,700 providers that are either employed by or affiliated with us(2), as of March 31, 2024. We hold a leading position in a majority of our markets, and we believe we are one of the leading healthcare systems based on market share and our integrated network of hospitals, ambulatory facilities, and physician practices(3). We operate either independently or in partnership with premier academic medical centers, large not-for-profit hospital systems, community physicians, and a community foundation through our well-established and differentiated JV model. Collectively, we operate as a unified organization with a consumer-centric approach to caring for our patients and our communities. Our healthcare delivery model is built around the consumer and seeks to optimize access for patients and continuity of care. We have built a comprehensive healthcare ecosystem that serves the unique needs of each patient over the course of his or her healthcare journey while our local physicians and providers deliver care based on the standard for their own market. We focus on establishing long-term relationships to engage with patients over their lifetime and seek to deliver superior, cost-effective health outcomes. On average, we care for more than 15,000 people every day across our healthcare ecosystem and during 2023, we served approximately 1.2 million unique patients who had approximately 5.4 million visits with our healthcare providers. We provide both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to our 30 acute care hospitals, we operate a broad network of ambulatory facilities and telehealth services, including 146 primary care and specialty care clinics, three ambulatory surgery centers (“ASCs”), 22 urgent care centers, two free-standing emergency departments, and ten diagnostic imaging centers. Bolstered by our provider network(4), which consists of more than 380 primary care providers and over 1,340 specialists, our network allows us to provide accessible and convenient healthcare to our patients in the optimal location, whether that be in a hospital, ambulatory care or virtual care setting. Our provider network enables us to participate in multiple collaborative accountable care organizations (“ACOs”), which are groups of hospitals, doctors, and other providers coming together to give coordinated quality care to patients. We believe this positions us favorably in the evolving healthcare reimbursement landscape. As part of our growth strategy, we are accelerating our ambulatory and physician alignment initiatives to expand both physical and virtual consumer access points. We expect that this approach will grow our market share and drive performance in connection with our value-based care initiatives, which are designed to deliver high-quality care that exceeds CMS benchmarks to patients in a cost-effective manner for payors. We leverage an advanced technology platform to drive enhanced care coordination and system productivity, which we believe leads to improved outcomes based on our safety of care, readmission, and mortality rates measured against applicable CMS benchmarks. This technology platform incorporates a variety of tools across our hospitals, clinics, and virtual care platforms and includes a consumer experience platform that drives our overall strategy to increase patient acquisition, engagement, and retention. We believe these technologies make it easier for caregivers to focus on delivering care, and for patients to access and receive care across all settings while also improving outcomes, such as safety of care, readmission, and mortality rates. Our well-established JV model differentiates us by enabling us to enhance our scale and provide unique opportunities to establish new markets and access points. In all of our eight regional markets, we have entered into JVs with premier academic medical centers, large not-for-profit hospital systems, community physicians, and a community foundation. Our strategic JV partners offer us significant advantages, including expanded access points, clinical talent availability, local brand recognition, and scale that enable us to accelerate market penetration. We help our partners enhance their network and regional presence through our operational acumen. We strengthen clinical services, drive operating improvements, and centrally manage operations to optimize hospital performance and enhance patient care. In each of these partnerships, we are the majority owner and serve as the day-to-day operator. We believe we are the JV partner-of-choice for academic medical centers and not-for-profit health systems in new and existing markets. Our hospital portfolio consists of 30 acute care hospitals, 18 of which are operated by JVs. Of those 18 hospitals, nine are owned and operated through limited liability companies (“LLCs”) that qualify as variable interest entities (“VIEs”). Through our wholly-owned subsidiaries, we own majority interests in each LLC that owns and operates our hospitals. While we hold majority interests in the LLCs that own and operate these hospitals, there are also significant minority interests held by not-for-profit medical systems, universities, academic medical centers, foundations or a combination thereof. The nine hospitals associated with the UT Health East Texas JV are wholly-owned by the JV’s members and, as such, do not represent hospitals owned and operated as VIEs. Instead, the UT Health East Texas facilities contribute earnings to the JV to be recognized by the members on a pro rata basis according to their ownership interests. For the year ended December 31, 2023, $1.6 billion of our revenue and $213.7 million of our net income was attributable to our JVs and VIEs, respectively. For the three months ended March 31, 2024, $415.9 million of our revenue and $51.4 million of our net income was attributable to our JVs and VIEs, respectively. Consequently, a significant portion of our revenue and net income is attributable to JVs and VIEs. While we believe that our relationships with our JV partners are strong, any changes in these relationships could disrupt ongoing business, negatively affect our cash flows and distract management and other key personnel from our core business operations. Additionally, the interests of our JV partners may differ from the interests of our Company as a whole, which could limit our ability to effectively operate the related JVs and maximize the economic benefits of our JV model. Since our inception in 2001, we have demonstrated an ability to consistently innovate and sustain organic growth during varied economic and regulatory climates. Additionally, our growth through acquisitions and JV partnerships has allowed us to enter new attractive markets. Between January 1, 2017 and March 1, 2018, we more than doubled the number of markets we serve and the number of hospitals we operate. While our business is rooted in acute care and other related services for surgery, complex medical conditions, or injuries, we have increased our ambulatory and physician footprint by adding more than 95 ambulatory facilities and 850 providers from 2017 to 2023 to create a comprehensive platform that supports the full continuum of patient care and participation in value-based care programs. Our significant investments and operational discipline have led to a more centralized and standardized organization, positioning us for continued growth and performance improvement in both new and existing areas. We operate in the large and growing healthcare services sector. According to CMS National Healthcare Expenditure Data, expenditures for hospital services and physician and clinical services collectively amounted to over $2.2 trillion in 2022, or 50% of the total healthcare spending in the United States. CMS estimates that these two types of expenditures together are projected to grow at an average rate of 5.7% annually through 2031. We estimate that our serviceable addressable market, which reflects the total hospital, physician and clinical services expenditures in markets that fit our strategic focus on mid-sized urban communities, approaches $800 billion. We believe we have significant opportunities to capture additional market share in our current markets and to expand into new markets. We have a disciplined approach to growth, which has led to improved financial and operating performance resulting in strong revenue, net income, and Adjusted EBITDA growth. From 2022 to 2023, we have grown total revenue from $5.1 billion to $5.4 billion, while net income decreased from $265.4 million to $129.0 million due to the non-recurring impact of a $157.8 million gain on the sale of a portfolio of medical office buildings during 2022 related to the MOB Transactions. Adjusted EBITDA increased from $296.9 million to $314.7 million over the same period. Adjusted EBITDA is a non-GAAP measure. (1) Based on number of hospitals. (2) Affiliated providers are physicians and advanced practice providers with whom we contract for their services through a professional services agreement or other independent contractor agreement. (3) Leading positions defined as first or second based on inpatient market share. (4) Provider network refers to our network of physicians and advanced practice providers that provide medical care at our facilities. Ardent Health Partners, LLC was formed in Delaware in 2015. Ardent Health Partners, LLC was formerly known as EGI-AM Holdings, L.L.C. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, Ardent Health Partners, LLC will convert into a Delaware corporation by means of a statutory conversion and change its name to Ardent Health Partners, Inc. Our principal executive offices are located at 340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027, and our telephone number is (615) 296-3000. Our internet website address is www.ardenthealth.com.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Ardent Health:

  • Like Marriott, but for hospitals.
  • A smaller, regional version of HCA Healthcare.

AI Analysis | Feedback

  • Acute Care Hospital Services: Providing a full spectrum of inpatient and outpatient medical and surgical care through their network of hospitals.
  • Physician Services: Offering primary and specialty care, including consultations, diagnostics, and treatments, through employed and affiliated physician practices.
  • Emergency Services: Delivering immediate medical attention for urgent and critical conditions via hospital emergency departments.

AI Analysis | Feedback

Ardent Health (symbol: ARDT) primarily sells its healthcare services directly to individuals. As a hospital operator and healthcare provider, its major customers are the patients who receive medical care through its network of hospitals, physician clinics, and urgent care centers. These customers can be broadly categorized as:

  • Patients Requiring Acute and Inpatient Hospital Care: These include individuals admitted to Ardent's hospitals for serious illnesses, injuries, complex surgeries, emergency medical conditions, or other treatments that necessitate an overnight stay and intensive medical attention.

  • Patients Utilizing Outpatient and Ambulatory Services: This category encompasses individuals who visit Ardent's facilities for services that do not require an overnight hospital stay. This includes appointments at physician clinics, urgent care visits, diagnostic imaging (e.g., X-rays, MRIs), laboratory tests, physical therapy, and various other specialized outpatient procedures and consultations.

  • Patients Seeking Specialized Programs and Chronic Disease Management: This group includes individuals participating in specific health programs such as maternity care, behavioral health services, rehabilitation, or those receiving ongoing, coordinated care for chronic medical conditions through Ardent's integrated health systems.

AI Analysis | Feedback

null

AI Analysis | Feedback

Marty Bonick, President & Chief Executive Officer

Mr. Bonick has served as President and CEO of Ardent Health Services since 2020. He has nearly 25 years of healthcare leadership experience across for-profit, non-profit, public, and privately held companies. Prior to Ardent, he was CEO of PhyMed Healthcare Group, a national provider of anesthesia and pain management services, where he drove significant growth organically and through acquisitions. He also served as a Division President at Community Health Systems (CHS), overseeing a $4.5 billion portfolio of 36 hospitals, and was CEO of Jewish Hospital and Senior Vice President of Operations for Jewish Hospital & St. Mary's Healthcare. Mr. Bonick began his career at Hillcrest HealthCare System, which Ardent Health Services acquired in 2004 during his tenure. Ardent Health Services is one of the largest private health systems in the U.S. and was backed by Equity Group Investments and Ventas Inc. at the time of his appointment, indicating a pattern of managing companies with private equity involvement.

Alfred Lumsdaine, Chief Financial Officer

Mr. Lumsdaine joined Ardent Health Services as CFO in 2021. With over 30 years of healthcare finance experience, he provides financial oversight and develops long-range financial plans. Before Ardent, he was Executive Vice President and CFO for Quorum Health from 2018 to 2021, where he oversaw financial operations for 22 acute care hospitals and led a major financial restructuring that significantly reduced company debt. Prior to Quorum Health, he was President of Population Health for Sharecare and spent five years as CFO for Tivity Health (formerly Healthways) before its acquisition by Sharecare, demonstrating experience with companies involved in acquisitions. He began his career at Ernst & Young, focusing on healthcare in the external audit practice. He is a Certified Public Accountant (CPA).

FJ Campbell, MD, Chief Medical Officer

Dr. Campbell has been with Ardent since 2017. Prior to joining Ardent, he served as the Vice President of Chief Medical Services at Community Health Systems (CHS) from 2014 to 2017. He also previously held the role of Chief Medical Officer for CareSpot Express Healthcare.

Steve Petrovich, Chief Legal Officer

Mr. Petrovich has been with Ardent since its formation in 2001 and previously served as general counsel for its predecessor company, Behavioral Health Corporation. Before that, he was chief litigation counsel for Charter Behavioral Health Systems and maintained a private legal practice specializing in general litigation, anti-trust, employment, and healthcare regulatory matters.

Carolyn Schneider, Chief Human Resources Officer

Ms. Schneider joined Ardent in 2021. She previously served as the Chief Human Resources Officer for Corizon Health, a prison healthcare contractor. Ms. Schneider has extensive experience working in the private equity-backed and investor-owned health system sectors.

AI Analysis | Feedback

Ardent Health (ARDT) faces several key risks to its business operations:
  • Accounting Adjustments and Legal Scrutiny: Ardent Health recently disclosed significant adverse accounting adjustments in Q3 2025, including a $43 million reduction in revenue and a $54 million increase in professional liability reserves related to prior period claims and ongoing litigation. These revelations led to a substantial decline in the company's stock price and prompted investigations by shareholder rights law firms into potential securities law violations and material weaknesses in internal controls regarding revenue recognition and liability reserves. This situation has also brought to light concerns about payer denials and reimbursement pressure.

  • Legislative and Reimbursement Risks: The company is exposed to significant legislative risks, particularly concerning potential cuts to government healthcare programs like Medicaid and Medicare. A substantial portion of Ardent Health's net patient service revenue is derived from these programs (40.5% from Medicare and 10.2% from Medicaid in Q1 2025). Legislative changes, such as proposed spending bills impacting Medicaid funding, introduce considerable uncertainty and can negatively affect the company's financial performance.

  • Staffing and Labor Shortages: Ardent Health faces ongoing challenges in recruiting and retaining qualified healthcare professionals, including nurses, physicians, and management personnel. Increased competition for skilled labor and a general shortage of experienced nurses could adversely impact the company's ability to operate efficiently and deliver services.

AI Analysis | Feedback

Clear Emerging Threats for Ardent Health (ARDT):

  • Accelerated Shift to Lower-Cost, Outpatient Care Settings: Advances in medical technology, less invasive procedures, and persistent payer pressures for cost containment are driving a significant and growing migration of procedures, diagnostics, and even certain types of surgeries from traditional, expensive inpatient hospital settings to ambulatory surgery centers (ASCs), outpatient clinics, and physician offices. This trend directly threatens the utilization and revenue streams of Ardent's core business of acute care hospitals, as patients and payers increasingly favor the convenience and lower cost of these alternative sites of care where clinically appropriate.
  • Expansion of Integrated Retail and Payer Health Ecosystems: Major retail corporations (e.g., CVS Health, Walgreens, Walmart) and large health insurers (e.g., UnitedHealth Group's Optum) are aggressively building and acquiring extensive direct-to-consumer health services networks. These ecosystems encompass primary care clinics, urgent care centers, specialty practices, and home health services, aiming to manage patient care comprehensively within their own integrated systems. This development introduces powerful new competitors that can divert patient volume, referrals, and market share away from independent hospital systems like Ardent, particularly for less acute conditions, primary care, and ongoing chronic disease management.

AI Analysis | Feedback

null

AI Analysis | Feedback

Ardent Health (symbol: ARDT) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

  1. Increased Patient Volumes: Ardent Health anticipates continued growth in patient volumes, specifically through adjusted admissions and surgeries. The company reported a 3.8% year-over-year increase in adjusted admissions in Q3 2024 and a significant 9.0% increase in Q4 2024. In Q2 2025, admissions grew 6.6% year-over-year, driven by a 9.2% increase in inpatient surgeries. For the full year 2025, Ardent Health projects adjusted admissions growth between 2.0% and 3.0%. This growth is supported by Ardent's strong positions in growing mid-sized urban markets and an aging patient population, which is expected to continue driving demand for healthcare services.

  2. Higher Net Patient Service Revenue per Adjusted Admission: The company expects to increase revenue through improved pricing and reimbursement rates. Ardent Health's full-year 2024 guidance projected net patient service revenue per adjusted admission growth of 2.3% to 4.4%. In Q2 2025, the company saw a 10.2% year-over-year growth in net patient service revenue per adjusted admission. This trend is expected to continue, with full-year 2025 guidance forecasting an increase between 2.1% and 4.4% in net patient service revenue per adjusted admission. Strategic initiatives also include optimizing payer contracts to enhance margins.

  3. Strategic Expansion of Outpatient Services and Acute Care Facilities: Ardent Health is actively pursuing an ambulatory growth strategy and opportunistic mergers and acquisitions (M&A) to expand its footprint and service offerings. The company plans to open additional urgent care and imaging centers, complementing recent acquisitions. This expansion beyond traditional hospital settings, particularly in outpatient services, is aimed at generating new revenue streams and positioning the company for value-based care. Ardent's strategic priorities emphasize driving market share within its existing footprint and expanding its outpatient and acute care hospital presence.

  4. State Directed Payment Programs and Operational Efficiencies: The approval and renewal of state-directed payment programs, such as the New Mexico Directed Payment Program (DPP), are significant contributors to revenue. The New Mexico DPP was retroactively approved in November 2024 for the second half of 2024, providing a substantial benefit to total revenue. Its renewal for the full calendar year 2025 is a positive development that will continue to support revenue. Additionally, Ardent Health is focused on operational excellence and margin improvement initiatives, including supply chain optimization and cost management, which are expected to lead to sustainable profitable growth and free up resources for further investment.

AI Analysis | Feedback

Share Issuance

  • Ardent Health went public in July 2024, raising $192 million in its initial public offering (IPO) by selling 12 million shares at $16 each.
  • After accounting for options granted to underwriters, the proceeds generated $209 million.
  • The proceeds from the IPO are expected to be allocated towards debt repayment and future acquisitions, with a particular focus on expanding ambulatory services and outpatient sites of care.

Inbound Investments

  • Equity Group Investments (EGI) remains a significant shareholder following Ardent Health's IPO in July 2024, having acquired a majority stake in the company in 2015.
  • In February 2022, Ardent completed a sale-leaseback transaction with Ventas, a related party REIT shareholder, selling 18 medical office buildings for $204 million.
  • Ardent Health has leveraged capital from private investors, public markets, a UAE minority investment, and a real estate investment trust.

Outbound Investments

  • In January 2025, Ardent Health acquired 18 urgent care clinics across New Mexico and Oklahoma from NextCare Urgent Care.
  • The company acquired nine additional urgent care centers in its East Texas and Topeka, Kansas, markets in 2024.
  • Ardent's strategy includes expanding its footprint in ambulatory care through acquisitions and growing its portfolio of joint ventures.

Capital Expenditures

  • Capital expenditures are expected to range from $215 million to $235 million for the full year 2025.
  • A primary focus for capital expenditures is investing in ambulatory assets, including both mergers and acquisitions (M&A) and de novo developments, to increase outpatient access points.
  • Capital investment also targets new service lines, equipment, and technology to expand offerings.

Trade Ideas

Select ideas related to ARDT. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
21.1%21.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-6.7%-6.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
16.7%16.7%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
11.8%11.8%-5.1%

Recent Active Movers

More From Trefis

Peer Comparisons for Ardent Health

Peers to compare with:

Financials

ARDTHCATHCUHSCYHSGRYMedian
NameArdent H.HCA Heal.Tenet He.Universa.Communit.Surgery . 
Mkt Price8.97474.06197.77227.083.2115.63106.70
Mkt Cap1.3113.417.414.30.42.08.1
Rev LTM6,32672,69820,84616,99312,6443,28814,818
Op Inc LTM37811,0783,3471,9491,0824991,516
FCF LTM1577,2921,502950143194572
FCF 3Y Avg1205,7041,678773-74168470
CFO LTM36711,9352,4781,9484932821,221
CFO 3Y Avg29310,4512,5501,641325257983

Growth & Margins

ARDTHCATHCUHSCYHSGRYMedian
NameArdent H.HCA Heal.Tenet He.Universa.Communit.Surgery . 
Rev Chg LTM10.9%6.4%-0.6%10.2%0.7%10.1%8.3%
Rev Chg 3Y Avg-6.6%3.1%8.7%0.9%10.4%6.6%
Rev Chg Q8.8%6.4%3.2%13.4%-0.1%6.6%6.5%
QoQ Delta Rev Chg LTM2.0%1.6%0.8%3.2%-0.0%1.6%1.6%
Op Mgn LTM6.0%15.2%16.1%11.5%8.6%15.2%13.3%
Op Mgn 3Y Avg5.4%15.0%13.8%9.8%7.3%14.7%11.8%
QoQ Delta Op Mgn LTM-1.0%0.1%0.4%0.5%1.6%0.8%0.4%
CFO/Rev LTM5.8%16.4%11.9%11.5%3.9%8.6%10.0%
CFO/Rev 3Y Avg5.2%15.4%12.3%10.5%2.6%8.6%9.5%
FCF/Rev LTM2.5%10.0%7.2%5.6%1.1%5.9%5.7%
FCF/Rev 3Y Avg2.1%8.4%8.1%4.9%-0.6%5.6%5.3%

Valuation

ARDTHCATHCUHSCYHSGRYMedian
NameArdent H.HCA Heal.Tenet He.Universa.Communit.Surgery . 
Mkt Cap1.3113.417.414.30.42.08.1
P/S0.21.60.80.80.00.60.7
P/EBIT3.010.44.87.20.34.94.9
P/E6.219.012.810.41.3-11.68.3
P/CFO3.59.57.07.30.97.07.0
Total Yield16.2%5.9%7.8%10.0%76.6%-8.6%8.9%
Dividend Yield0.0%0.6%0.0%0.4%0.0%0.0%0.0%
FCF Yield 3Y Avg-6.4%13.5%6.1%-20.8%5.0%6.1%
D/E1.80.40.80.426.21.91.3
Net D/E1.30.40.60.325.91.81.0

Returns

ARDTHCATHCUHSCYHSGRYMedian
NameArdent H.HCA Heal.Tenet He.Universa.Communit.Surgery . 
1M Rtn-1.8%-8.0%-9.5%-6.8%-7.5%-7.5%-7.5%
3M Rtn-32.0%14.4%0.5%15.0%0.9%-27.6%0.7%
6M Rtn-32.6%25.9%14.6%28.2%-7.8%-28.0%3.4%
12M Rtn-44.2%56.8%52.5%25.8%2.2%-25.6%14.0%
3Y Rtn-101.8%324.0%63.6%-17.3%-41.4%63.6%
1M Excs Rtn-2.4%-8.6%-11.2%-7.5%-8.7%-7.4%-8.1%
3M Excs Rtn-36.9%9.5%-4.4%10.0%-4.0%-32.6%-4.2%
6M Excs Rtn-45.5%13.1%1.7%15.3%-20.6%-40.9%-9.5%
12M Excs Rtn-60.9%40.4%35.9%9.7%-15.3%-43.2%-2.8%
3Y Excs Rtn-21.9%271.8%-10.3%-95.5%-120.2%-10.3%

Financials

Segment Financials

Revenue by Segment
$ Mil202420232022
Other managed care2,3052,1362,054
Medicare2,1372,0841,944
Medicaid607589541
Self-pay and other268220232
Other revenue93100100
Total5,4095,1304,870


Price Behavior

Price Behavior
Market Price$8.97 
Market Cap ($ Bil)1.3 
First Trading Date07/18/2024 
Distance from 52W High-47.5% 
   50 Days200 Days
DMA Price$11.26$15.04
DMA Trenddowndown
Distance from DMA-20.4%-40.4%
 3M1YR
Volatility75.6%56.8%
Downside Capture280.1891.29
Upside Capture38.2019.74
Correlation (SPY)30.7%25.8%
ARDT Betas & Captures as of 11/30/2025

 1M2M3M6M1Y3Y
Beta3.552.222.031.730.780.22
Up Beta-1.49-0.76-0.311.400.79-0.01
Down Beta10.524.804.724.020.96-0.15
Up Capture32%56%45%10%22%5%
Bmk +ve Days12253873141426
Stock +ve Days7203263120168
Down Capture561%305%244%175%101%75%
Bmk -ve Days7162452107323
Stock -ve Days11202959121167

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
null
Based On 5-Year Data
null
Based On 10-Year Data
null

Short Interest

Short Interest: As Of Date12152025
Short Interest: Shares Quantity2,749,483
Short Interest: % Change Since 113020251.2%
Average Daily Volume613,095
Days-to-Cover Short Interest4.48
Basic Shares Quantity141,226,862
Short % of Basic Shares1.9%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/2025-33.8%-38.6%-36.7%
8/5/20256.1%17.1%20.8%
2/26/20258.2%9.4%-6.1%
11/6/20247.8%4.5%2.3%
8/14/20246.1%5.7%13.4%
SUMMARY STATS   
# Positive443
# Negative112
Median Positive7.0%7.5%13.4%
Median Negative-33.8%-38.6%-21.4%
Max Positive8.2%17.1%20.8%
Max Negative-33.8%-38.6%-36.7%

SEC Filings

Expand for More
Report DateFiling DateFiling
93020251114202510-Q 9/30/2025
6302025806202510-Q 6/30/2025
3312025507202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024814202410-Q 6/30/2024
123120237182024424B4 12/31/2023
123120183062019S-1/A 12/31/2018
1231201712212018S-1/A 12/31/2017